SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1474 547X srt2:(2000-2009)"

Sökning: L773:1474 547X > (2000-2009)

  • Resultat 1-10 av 249
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  • Abe, O, et al. (författare)
  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  • 2005
  • Ingår i: The Lancet. - 1474-547X. ; 365:9472, s. 1687-1717
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5-year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxombicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modem aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50-69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0 . 0001 for recurrence, 2p<0 . 00001 for breast cancer mortality) more effective than CMF chemotherapy. Few women of age 70 years or older entered these chemotherapy trials. For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age (<50, 50-69, &GE; 70 years), progesterone receptor status, or other tumour characteristics. 5 years is significantly (2p<0 . 00001 for recurrence, 2p=0 . 01 for breast cancer mortality) more effective than just 1-2 years of tamoxifen. For ER-positive tumours, the annual breast cancer mortality rates are similar during years 0-4 and 5-14, as are the proportional reductions in them by 5 years of tamoxifen, so the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1-2 years of tamoxifen versus none (33 000); and about 5 years versus 1-2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age <50 years) and 20% (age 50-69 years) from such chemotherapy were followed by a further reduction of 31% from tamoxifen in the risks that remain, the final mortality reductions would be 57% and 45%, respectively (and, the trial results could well have been somewhat stronger if there had been full compliance with the allocated treatments). Overall survival would be comparably improved, since these treatments have relatively small effects on mortality from the aggregate of all other causes. Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs.
  •  
5.
  •  
6.
  • Ahlberg, Karin, 1965, et al. (författare)
  • Assessment and management of cancer-related fatigue in adults.
  • 2003
  • Ingår i: Lancet. - 1474-547X. ; 362:9384, s. 640-50
  • Forskningsöversikt (refereegranskat)abstract
    • Fatigue is one of the most prevalent and distressing symptoms of cancer, and is a common side-effect of many of the treatments available for the management of malignant disease. We critically assess the evidence for cancer-related fatigue and its treatment in adults. Little is known about the cause and mechanisms of fatigue, and research into methods of alleviating the condition has focused on treatment for anaemia and behavioural interventions, such as exercise, both of which are effective in reducing fatigue. Although research into the condition has increased considerably in the past decade, important gaps in knowledge remain.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  • Amer-Wåhlin, Isis, et al. (författare)
  • Cardiotocography only versus cardiotocography plus ST analysis of fetal electrocardiogram for intrapartum fetal monitoring: a Swedish randomised controlled trial
  • 2001
  • Ingår i: The Lancet. - 1474-547X. ; 358:9281, s. 534-538
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Previous studies indicate that analysis of the ST waveform of the fetal electrocardiogram provides information on the fetal response to hypoxia. We did a multicentre randomised controlled trial to test the hypothesis that intrapartum monitoring with cardiotocography combined with automatic ST-waveform analysis results in an improved perinatal outcome compared with cardiotocography alone. METHODS: At three Swedish labour wards, 4966 women with term fetuses in the cephalic presentation entered the trial during labour after a clinical decision had been made to apply a fetal scalp electrode for internal cardiotocography. They were randomly assigned monitoring with cardiotocography plus ST analysis (CTG+ST group) or cardiotocography only (CTG group). The main outcome measure was rate of umbilical-artery metabolic acidosis (pH <7.05 and base deficit >12 mmol/L). Secondary outcomes included operative delivery for fetal distress. Results were first analysed according to intention to treat, and secondly after exclusion of cases with severe malformations or with inadequate monitoring. FINDINGS: The CTG+ST group showed significantly lower rates of umbilical-artery metabolic acidosis than the cardiotocography group (15 of 2159 [0.7%] vs 31 of 2079 [2%], relative risk 0.47 [95% CI 0.25-0.86], p=0.02) and of operative delivery for fetal distress (193 of 2519 [8%] vs 227 of 2447 [9%], 0.83 [0.69-0.99], p=0.047) when all cases were included according to intention to treat. The differences were more pronounced after exclusion of 291 in the CTG+ST group and 283 in the CTG group with malformations or inadequate recording. INTERPRETATION: Intrapartum monitoring with cardiotocography combined with automatic ST-waveform analysis increases the ability of obstetricians to identify fetal hypoxia and to intervene more appropriately, resulting in an improved perinatal outcome.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 249
Typ av publikation
tidskriftsartikel (238)
forskningsöversikt (7)
annan publikation (3)
konferensbidrag (1)
Typ av innehåll
refereegranskat (206)
övrigt vetenskapligt/konstnärligt (41)
populärvet., debatt m.m. (2)
Författare/redaktör
Yusuf, S. (8)
Collins, R (7)
Olofsson, B (6)
Bergh, J (5)
Olsson, Håkan (4)
Cameron, D. (4)
visa fler...
Malmström, Per (4)
Hall, E (4)
Davies, C (4)
Rosso, R (3)
Schumacher, M. (3)
Wang, X. (3)
Steinberg, S (3)
Nilsson, J. (3)
Brown, A. (3)
Ivanov, V. (3)
Wang, Y. (3)
Gnant, M. (3)
Jonat, W. (3)
Thürlimann, B. (3)
KLARESKOG, L (3)
James, S. (3)
Jackson, S. (3)
Soderberg, M (3)
Lee, M (3)
Anderson, S (3)
Brenner, H (3)
Cross, M (3)
Hill, C. (3)
Costa, A. (3)
Swedberg, Karl, 1944 (3)
Martin, P. (3)
McMurray, J. J. (3)
Yoshida, M. (3)
Abe, O (3)
Abe, R (3)
Enomoto, K (3)
Kikuchi, K (3)
Koyama, H (3)
Masuda, H (3)
Nomura, Y (3)
Sakai, K (3)
Sugimachi, K (3)
Tominaga, T (3)
Uchino, J (3)
Haybittle, JL (3)
Harvey, VJ (3)
Holdaway, TM (3)
Kay, RG (3)
Mason, BH (3)
visa färre...
Lärosäte
Karolinska Institutet (108)
Lunds universitet (46)
Uppsala universitet (38)
Umeå universitet (32)
Linköpings universitet (29)
Göteborgs universitet (25)
visa fler...
Stockholms universitet (6)
Örebro universitet (2)
Handelshögskolan i Stockholm (2)
Högskolan i Gävle (1)
Södertörns högskola (1)
Linnéuniversitetet (1)
Högskolan Dalarna (1)
Marie Cederschiöld högskola (1)
visa färre...
Språk
Engelska (249)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (87)
Samhällsvetenskap (9)
Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy